These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32557009)

  • 1. Quantifying Patient Subpopulation Disparities in New Drugs and Biologics Approved Between 2007 and 2017.
    Getz KA; Smith ZP; Peña Y
    Ther Innov Regul Sci; 2020 Nov; 54(6):1541-1550. PubMed ID: 32557009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demographic diversity of US-based participants in GSK-sponsored interventional clinical trials.
    Reid MM; Davis SP; Henry ON; Mathew AA; McCallister S; Nero TT; Rabheru SA; Sampson SH; Vanderslice TF; Williams DT
    Clin Trials; 2023 Apr; 20(2):133-144. PubMed ID: 36744680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying Diversity and Representation in Pivotal Trials Leading to Marketing Authorization in Europe.
    Smith Z; Botto E; Getz K
    Ther Innov Regul Sci; 2022 Sep; 56(5):795-804. PubMed ID: 35680722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.
    Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS
    Trials; 2016 Apr; 17():199. PubMed ID: 27079511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying Clinical Trial Diversity in Pivotal Registration Trials of FDA Novel Drug Approvals.
    Idris MY; Fitzsimmons WE; Pemu P
    Ther Innov Regul Sci; 2024 Jan; 58(1):175-183. PubMed ID: 37872439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Benchmarks on Demographic Disparities in Pivotal Trials Supporting FDA-Approved Drugs and Biologics.
    Smith Z; Botto E; Johnson O; Rudo T; Getz K
    Ther Innov Regul Sci; 2024 Jan; 58(1):143-152. PubMed ID: 37775684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: retrospective cross sectional study.
    Varma T; Mello M; Ross JS; Gross C; Miller J
    BMJ Med; 2023; 2(1):e000395. PubMed ID: 36936269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Drug Formulary Management and Utilization: Evidence in Sex, Race, and Ethnicity: 2019-2020.
    Keeys CA; Harding BW; Migneco GE; Rahini SS; Coleman HB
    Ann Pharmacother; 2022 Feb; 56(2):139-145. PubMed ID: 34049437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of race/ethnicity in trials leading to anti-rheumatic drug approval for inflammatory arthritis by the US Food and Drug Administration.
    Xie Y; Liu Y; Qin Y; Chen X; Xie Q
    Int J Rheum Dis; 2023 Dec; 26(12):2489-2497. PubMed ID: 37854006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
    Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
    Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015.
    Chen A; Wright H; Itana H; Elahi M; Igun A; Soon G; Pariser AR; Fadiran EO
    J Womens Health (Larchmt); 2018 Apr; 27(4):418-429. PubMed ID: 29048983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Disparities and Black American Representation in Clinical Trials Leading to the Approval of Oral Chemotherapy Drugs in the United States Between 2009 and 2019.
    Ajewole VB; Akindele O; Abajue U; Ndulue O; Marshall JJ; Mossi YT
    JCO Oncol Pract; 2021 May; 17(5):e623-e628. PubMed ID: 33974825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Despite The FDA's Five-Year Plan, Black Patients Remain Inadequately Represented In Clinical Trials For Drugs.
    Green AK; Trivedi N; Hsu JJ; Yu NL; Bach PB; Chimonas S
    Health Aff (Millwood); 2022 Mar; 41(3):368-374. PubMed ID: 35254926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients?
    Fox-Rawlings SR; Gottschalk LB; Doamekpor LA; Zuckerman DM
    Milbank Q; 2018 Sep; 96(3):499-529. PubMed ID: 30203600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demographic Disparities in the Federal Drug Approval Process for Allergic Rhinitis Medications.
    Liebowitz A; Spielman DB; Schlosser RJ; Stewart MG; Gudis DA
    Laryngoscope; 2023 Apr; 133(4):755-763. PubMed ID: 35394648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining participant representation by sex, race, ethnicity and age in United States blood donation and blood transfusion clinical trials.
    Muir R; Jacobs JW; Flores LE; Marshall AL; Ansari ES; Booth GS; Silver JK
    Transfus Apher Sci; 2023 Jun; 62(3):103653. PubMed ID: 36781328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Representation of sex, race, and ethnicity in pivotal clinical trials for dermatological drugs.
    Ding J; Zhou Y; Khan MS; Sy RN; Khosa F
    Int J Womens Dermatol; 2021 Sep; 7(4):428-434. PubMed ID: 34621955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Participation of racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular entities approved 1995-1999.
    Evelyn B; Toigo T; Banks D; Pohl D; Gray K; Robins B; Ernat J
    J Natl Med Assoc; 2001 Dec; 93(12 Suppl):18S-24S. PubMed ID: 11798060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of worldwide clinical trials by gender: An FDA perspective.
    Ayuso E; Geller RJ; Wang J; Whyte J; Jenkins M
    Contemp Clin Trials; 2019 May; 80():16-21. PubMed ID: 30890465
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.